Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update

Swati Sucharita Mohanty; Chita Ranjan Sahoo; Rabindra Nath Padhy

doi:10.1016/j.gendis.2020.12.005

您当前的位置：

首页 >

文章列表页 >

Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update

Review article | 更新时间：2022-06-24

- Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update
- Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update
- Genes & Diseases 2022年9卷第3期
- 作者机构：
  
  1. Cytogenetics Laboratory, P.G. Department of Zoology, Utkal University,, Odisha,Bhubaneswar,India,751004
  2. Central Research Laboratory, Institute of Medical Sciences & SUM Hospital, Siksha ‘O’ Anusandhan Deemed to be University,, Odisha,Bhubaneswar,India,751003
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.12.005
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-5-1，
扫描看全文
Swati Sucharita Mohanty, Chita Ranjan Sahoo, Rabindra Nath Padhy. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update[J]. Genes & Diseases, 2022,9(3).

Swati Sucharita Mohanty, Chita Ranjan Sahoo, Rabindra Nath Padhy. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update[J]. Genes & Diseases, 2022,9(3).
Swati Sucharita Mohanty, Chita Ranjan Sahoo, Rabindra Nath Padhy. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update[J]. Genes & Diseases, 2022,9(3). DOI： 10.1016/j.gendis.2020.12.005.

Swati Sucharita Mohanty, Chita Ranjan Sahoo, Rabindra Nath Padhy. Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update[J]. Genes & Diseases, 2022,9(3). DOI： 10.1016/j.gendis.2020.12.005.

摘要

Abstract

This review provides an updated account on the current methods

principles and mechanism of action of therapies for the detection of molecular markers of therapeutic importance in the prognosis of breast cancer progression and recurrence

which includes estrogen receptor (ER)

progesterone receptor (PR) and human epidermal growth factor receptor2 (HER2). Indeed

hormone-receptors namely

proto-oncogene

HER2

are the basic molecular markers that are recognized and established prognostic factors and predictors of response

for therapeutic practice. These markers can be detected by using immunohistochemistry (IHC) and fluorescence

in situ

hybridization (FISH)

which are established

faster and cost effective detection methods. These molecular markers along with clinicopathological prognostic parameters give the best prediction of the prognosis of cancer recurrence and progress. Finally

hormone receptors and HER2 as molecular markers are of prime therapeutic importance and have the capability to take part in future drug development techniques.

关键词

Keywords

Breast cancerMolecular diagnosticMolecular markersPredictive markersPrognostic

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Hippo-YAP/TAZ signaling in breast cancer: Reciprocal regulation of microRNAs and implications in precision medicine

Mitochondria-related signaling pathways involved in breast cancer regulate ferroptosis

Zinc finger protein 831 promotes apoptosis and enhances chemosensitivity in breast cancer by acting as a novel transcriptional repressor targeting the STAT3/Bcl2 signaling pathway

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Zinc-finger protein 382 antagonises CDC25A and ZEB1 signaling pathway in breast cancer